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ThrombocytopeniaAbstract Background: Hemogram or complete blood count (CBC) is one of essential laboratory
tests either in the diagnosis or assessment of community acquired pneumonia (CAP) patients.
Objective: To assess the role of leukocyte and platelet count in determination of the severity and
outcome of CAP.
Patients and methods: This is a prospective descriptive study which was done on 95 patients aged
P18 years, who were diagnosed to have CAP. Clinical, laboratory and chest radiographic ﬁnding
data were collected for each patient. Assessment of CAP severity using Pneumonia Severity Index
(PSI) and CRB-65 score (the confusion, respiratory rate, blood pressure plus ageP65) was done for
all enrolled patients. Thrombocytopenia and thrombocytosis were deﬁned as platelet count
<100,000/lL and 400,000/lL, respectively. Leukopenia and leukocytosis were deﬁned as WBC
count of <4000/lL and >11,000/lL, respectively. The outcome variable was in-hospital mortality.
Results: In this study 75 (78.9%) of patients improved (survivors) and the outcome of 20
(21.1%) patients was in-hospital mortality (non-survivors). PS-index score III, IV and V and
CRB-65 score II, III and IV were signiﬁcantly higher in patients with thrombocytosis
(P< 0.006, P< 0.04 respectively) while there was no signiﬁcant difference as regards leukocyte
count in both scores. Also both thrombocytopenia and thrombocytosis were signiﬁcantly higher
in non survivors (P< 0.006) while there was no signiﬁcant difference as regards leukocytosis.
Platelet count has a signiﬁcant positive correlation with CRB-65 and PS index with P-value
0.001 for each and r-value 0.236, 0.259 respectively.
Conclusion: On assessment of CAP patients at admission; platelet count could be considered to
be a valuable indicator of severity and outcome on evaluating hemogram (CBC) values than the
more commonly used leukocyte count.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Up till now community acquired pneumonia (CAP) still has
signiﬁcant morbidity and mortality especially with the emer-
gent pathogens that presented with aggressive pictures ofrculosis.
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States. In the world of community acquired pneumonia early
and adequate severity assessment and treatment are recom-
mended to improve morbidity and mortality of CAP.
Usually patients were treated according to international guide-
lines, and scores of severity were used to classify patients that
help to decide the site of care in CAP patients [1].
Hemogram or complete blood count (CBC) is one of essen-
tial laboratory tests either in the diagnosis or assessment of
CAP patients where leukocyte values are considered as an indi-
cation of systemic inﬂammatory response and severity of dis-
ease. Recently, being part of the hemostatic process, platelets
have been increasingly recognized as an important component
of the immune response to infection similar to the leukocyte
response [2–4]. It has been evidenced that platelets play a
major role in antimicrobial host defense in different ways sim-
ilar to the leukocyte response as both cell types contain antimi-
crobial peptides to kill a broad range of pathogens [2].
Activation of platelets by agonists enhances platelet interac-
tions with complement proteins and humoral immune compo-
nents, as well as leukocytes and endothelial cells. Leukocytes
need to phagocytize bacteria to achieve interaction with intra-
cellular peptides; also platelets are capable of binding, aggre-
gating and internalizing microorganisms into phagosome-like
vacuoles, which enhances the clearance of pathogens from
bloodstream and release potent antimicrobial peptides that
participate in antibody dependent cell cytotoxicity functions
to kill pathogens [5]. Inﬂammatory thrombocytosis is related
to increased levels of several cytokines such as thrombopoietin,
interleukin-6, interleukin-1alpha, interleukin-8 and tumor
necrosis factor alpha [6]. Studies revealed that severe CAP is
associated with signiﬁcant increment of plasma levels of the
inﬂammatory cytokines TNF-a, IL-1b, IL-6, IL-8 [7,8].
Although many scores have been established to evaluate the
severity and outcome of CAP, we are in real need to a clinically
rapid and reliable method for assessment.
The aim of this study is to assess the role of two compo-
nents of hemogram; one of them is leukocyte count and the
other is platelet count, in determination of severity and out-
come of CAP.Patients and methods
This is a prospective descriptive study which was done on 95
patients aged P18 years, who were diagnosed to have CAP.
All of them were admitted to Chest Department, Assiut
University Hospitals between September 2013 and December
2014. CAP was deﬁned [9] as the presence of a new pulmonary
inﬁltrate on chest radiograph at the time of hospital admission
associated with at least one of the following: (1) new or
increased symptoms and signs of lower respiratory tract infec-
tion, (2) an abnormal temperature (35.6 C or 37.8 C), (3) an
abnormal serum leukocyte count (leukocytosis, left shift, or
leukopenia deﬁned by local laboratory values). We excluded
patients with previous use of oral corticosteroids (P10 mg
prednisone equivalent per day for at least 2 weeks); other
immunosuppressive therapy; tuberculosis; HIV infection;
active solid or hematologic neoplasm; hematologic disease
involving platelets and/or leukocytes, such as essential throm-
bocytosis or myelodysplastic syndrome, patients on anti-
platelet or anticoagulant drugs; and hospitalization withinthe preceding 21 days. Clinical and laboratory data were col-
lected for each patient. These include patient’s demographic,
clinical presentation, comorbidity, physical examination, labo-
ratory (CBC, liver function, arterial blood gas, serum urea and
creatinine, serum electrolyte) and chest radiographic ﬁndings.
Thrombocytopenia and thrombocytosis were deﬁned as plate-
let counts <100,000/lL or >400,000/lL, respectively [10].
Leukopenia and leukocytosis were deﬁned as WBC counts of
<4000/lL and >11,000/lL, respectively [11]. Assessment of
CAP severity at time of hospital admission using Pneumonia
Severity Index (PSI) [12] and CRB-65 score (the confusion, res-
piratory rate, blood pressure plus age P65) [13] was done for
all enrolled patients. The outcome variable was in hospital
mortality.
Statistical analysis
Analysis was performed using the statistical software (SPSS
version 17; SPSS, Inc., Chicago, IL, USA). Data are presented
as mean ± SD for continuous variables or frequency (percent-
age) for categorical variables, using v2-test to compare qualita-
tive data while two-sampled unpaired t-test for quantitative
data. P value of <0.05 was considered signiﬁcant. The corre-
lation of parameters with each other was investigated by the
Pearson correlation test. Discriminative diagnostic values
including sensitivity, speciﬁcity, and receiver operating charac-
teristic (ROC) curve were assessed by medical tests.
Results
This study done upon 95 CAP patients where 75 (78.9%) of
them improved (survivors) and the outcome of 20 (21.1%)
patients was in hospital mortality (non-survivors). Patient
characteristics are described in Table 1 where age is signiﬁ-
cantly older in non-survivors patients. Also length of hospital
stay, patients on empirical antibiotics before hospital admis-
sion and comorbidity (Fig. 1) were signiﬁcantly higher in those
patients. Table 2 shows that PS-index score IV and V and
CRB-65 score II, III and IV are signiﬁcantly higher in non-
survivors patients with P< 0.000. Normal platelet count
was detected in 64 (67.4%) patients, thrombocytosis in 26
(27.4%) patients and thrombocytopenia in 5 (5.2%) patients,
while normal leukocyte count was revealed in 26 (27.4%),
leukopenia in two (2.1%) patients and leukocytosis in 67
(70.5%). Table 3 reveals that both thrombocytopenia and
thrombocytosis were signiﬁcantly higher in non survivors
(P< 0.006) while there was no signiﬁcant difference as regards
leukocyte count.
As regards severity assessment of CAP patients; Table 4
reveals that PS-index score III, IV and V and CRB-65 score
II, III and IV were signiﬁcantly higher in patients with throm-
bocytosis (P< 0.006, P< 0.048 respectively) while there was
no signiﬁcant difference as regards leukocyte counts in both
scores (Table 5).
There is a signiﬁcant positive correlation between platelet
counts with both CRB-65 and PSI scores (r-value 0.335,
0.259, respectively) with P< 0.022, <0.011 respectively, also
there is a signiﬁcant positive correlation between leukocyte
counts with both CRB-65 and PSI scores (r-value 0.319,
0.253, respectively) with P< 0.002, <0.013 respectively
(Figs. 2–5).
Table 1 Characteristics of 95 CAP patients enrolled in this study.
Survivors (n= 75) Non-survivors (n= 20) P-value
Age: (years) Mean ± SD 44.13 ± 16.65 55.05 ± 15.93 0.015*
Male: No. (%) 51 (68.0%) 15 (75.0%) 0.546
Female: No. (%) 24 (32.0%) 5 (25.0%)
Smoker: No. (%) 27 (36.0%) 12 (60.0%) 0.043*
LOH stay: (days) Mean ± SD 6.21 ± 2.26 11.25 ± 5.93 0.000*
Comorbidity: No. (%)
Chronic heart disease 4 (5.3%) 1 (5%) 0.953
Chronic pulmonary disease 20 (26.7%) 9 (45%) 0.114
Chronic renal disease 4 (5.3%) 1 (5%) 0.953
Chronic liver disease 2 (2.7%) 2 (10%) 0.410
Neoplastic disease 2 (2.7%) 2 (10%) 0.410
Diabetes mellitus 9 (12%) 3 (15%) 0.720
Previous antibiotic: No. (%) 19 (25.3%) 12 (60.0%) 0.003*
Clinical ﬁnding
Cough, No. (%) 67 (89.3%) 16 (80%) 0.461
Altered mental status, No. (%) 4 (5.3%) 7 (35%) 0.001*
Consolidation, No. (%) 32 (42.7) 9 (45%) 0.852
Temperature, Mean ± SD 38.31 ± 0.60 38.85 ± 0.79 0.001*
Heart rate, Mean ± SD 104.04 ± 17.34 115.05 ± 17.88 0.01*
Respiratory rate, Mean ± SD 26.17 ± 7.93 33.20 ± 6.80 0.000*
Systolic BP, Mean ± SD 120.40 ± 18.99 114.50 ± 17.01 0.204
Diastolic BP, Mean ± SD 74.93 ± 11.78 69.00 ± 14.10 0.04*
Laboratory and CXR ﬁnding
S. Albumin (mg/dl) Mean ± SD 27.85 ± 6.08 23.24 ± 5.23 0.003
S. Urea (mg/dl) Mean ± SD 9.28 ± 8.33 14.00 ± 12.26 0.113
S. Creatinine (mg/dl) Mean ± SD 129.97 ± 13.49 179.75 ± 29.66 0.096
S. Sodium (mg/dl) Mean ± SD 133.88 ± 5.34 131.20 ± 6.35 0.019*
H, Mean ± SD 7.42 ± 0.07 7.39 ± 0.12 0.184
PaO2, Mean ± SD 67.00 ± 16.43 58.80 ± 17.74 0.046
*
Multilobar CXR inﬁltrate, No. (%) 15 (20%) 11 (55%) 0.002
LOH: length of hospital stay, CXR: chest X-ray.
* Signiﬁcant P-value.
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Figure 1 Comorbidity in relation to in hospital mortality of 95
CAP patients.
Table 3 Platelet and leukocyte counts in relation to in
hospital mortality of 95 CAP patients.
Survival
(n= 75)
Non-survival
(n= 20)
P-value
No. % No. %
Platelet count 0.006*
Thrombocytopenia 2 2.7 3 15
Normal 56 74.7 8 40
Thrombocytosis 17 22.6 9 45
Leukocyte count 0.858
Normal 21 28 5 25
Leukocytosis 53 70.6 14 70
Leukopenia 1 1.3 1 5
* Signiﬁcant P-value.
Table 2 PS-index and CRB-65 scores in relation to in hospital
mortality of 95 CAP patients.
Survivors
(n= 75)
Non-
survivors
(n= 20)
P-value
No. % No. %
PS-index Score 0.000*
PS-index I & II 45 60.00 0 0.0
PS-index III 17 22.7 5 25.00
PS-index IV & V 13 17.3 15 75.00
CRB-65 Score 0.000*
CRB-65 0 24 32 0 0.0
CRB-65 I 24 32 0 0.0
CRB-65 II & III & IV 27 36 20 100
* Signiﬁcant P-value.
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mortality with cutoff point >346 · 103/lL that has the best
sensitivity and speciﬁcity (Sensitivity = 85%,
Speciﬁcity = 72%) and an area under the ROC curve
(AUC) = 0.819. Also Fig. 7 reveals that leukocyte count could
predict in hospital mortality with cutoff point >17 · 103/lL
but with less sensitivity and speciﬁcity (Sensitivity = 70%,
Speciﬁcity = 69%) and also less area under the ROC curve
(AUC) = 0.648.
Table 4 Platelet counts in relation to CRB-65 and PS-index
scores of 95 CAP patients.
Platelet count P value
Normal
(n= 64)
Thrombocytosis
(n= 26)
No. % No. %
CRB-65 score 0.048
CRB-65 0 21 32.8 3 11.5
CRB-65 I 17 26.6 6 23.1
CRB-65 II, III, IV 26 40.6 17 65.4
PS-index score 0.006
PS-index I & II 38 59.4 6 23.1
PS-index III 13 20.3 8 30.7
PS-index IV & V 13 20.3 12 46.2
Table 5 Leukocyte count in relation to CRB-65 and PS-index
scores of 95 CAP patients.
Leukocyte count P-value
Normal
(n= 26)
Leukocytosis
(n= 67)
No. % No. %
CRB-65 score 0.481
CRB-65 0 9 34.6 15 22.4
CRB-65 I 6 23.1 18 26.9
CRB-65 II, III, IV 11 42.3 34 50.7
PS-index 0.442
PS-index I & II 15 57.7 30 44.8
PS-index III 6 23.1 16 23.9
PS-index IV & V 5 19.2 21 31.3
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Severity assessment is a fundamental tool in the management
of pneumonia that allows patients to be stratiﬁed according
to risk of death and the most appropriate treatment intensity
to be provided. The most widely used scales are the PSI/FineFigure 2 Correlation between platelet counand CRB-65 scales, which have been widely validated and
are easy to calculate in clinical practice. One of ﬁrst aid mea-
surements in the evaluation of CAP patient is to do complete
blood count (CBC) while the leukocyte count is the usual value
evaluated to guide clinical assessment of CAP patients.
In this work normal platelet count was detected in 64
(67.4%) patients, thrombocytosis in 26 (27.4%) patients and
thrombocytopenia in 5 (5.2%) patients. Thrombocytosis and
thrombocytopenia were signiﬁcantly higher in patients with
in-hospital mortality and also in higher class scores of both
CRB-65 and PS-index while leukocyte count has no signiﬁcant
difference as regards mortality and different classes of both
scores.
Mirsaeidi et al. [14] studied 500 CAP patients, of whom
thrombocytosis presented in 65 (13%) and thrombocytopenia
presented in 27 (5%) and reported that both patients with
thrombocytopenia and those with thrombocytosis had signiﬁ-
cantly higher mortality and did not ﬁnd an association
between leukocyte count and mortality, so an increase of pla-
telet count appeared to better identify patients with higher
mortality risk. In contrast Prina et al. (2013) evaluated 3010
patients with CAP, where 2423 met their inclusion criteria
and found that thrombocytosis presented in 204 (8%) and
thrombocytopenia presented in 53 (2%), patients with throm-
bocytosis had lower CRB-65 score at admission however
patients with thrombocytosis and those with thrombocytope-
nia had higher mortality rate in accordance with our results
[15].
In this study there was a positive correlation between both
platelet and leukocyte count with in-hospital mortality how-
ever platelet count could predict in-hospital mortality with cut-
off point >346 · 103/lL with better AUC (0.819) than that of
leukocyte count (0.648). Prina et al. [15] found that there was a
signiﬁcant correlation between thrombocytosis and mortality
and adding it to CRB-65 score improves the accuracy to pre-
dict mortality with AUC 0.654. Recent study revealed that
thrombocytosis was strongly associated with CAP severity
parameters and more signiﬁcant than abnormal leukocyte
count in predicting the severity of CAP [16]. Also Mirsaeidi
et al. [14] found that higher platelet count was associated with
signiﬁcant increased risk of mortality.t and CRB-65 score of 95 CAP patients.
Figure 3 Correlation between platelet count and PS-index score of 95 CAP patients.
Figure 4 Correlation between leukocyte count and CRB-65 score of 95 CAP patients.
Figure 5 Correlation between leukocyte count and PS-index score of 95 CAP patients.
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Figure 6 Receiver operating characteristic (ROC) curve for platelet counts in predicting in-hospital mortality of 95 CAP patients with
area under the curve (AUC) of 0.819.
Figure 7 Receiver operating characteristic (ROC) curve for leukocyte counts in predicting in-hospital mortality of 95 CAP patients with
area under the curve (AUC) of 0.648.
622 L.H. Shaaban, Y. AhmedIt is known that abnormalities in the coagulation system
can be due to low as well as high platelet count. So thrombo-
cytosis may favor an exaggerated systemic inﬂammatory
response that, in turn, produces poor outcomes in patients
with CAP. Besides this mechanism of platelet induced systemic
inﬂammation, another possible mechanism is platelet-induced
thrombus formation. Also thrombocytopenia is recognized
as a marker of poor outcomes in patients with pneumonia,
due to the association of low platelet counts with disseminated
intravascular coagulation and severe sepsis.
In conclusion, on assessment of CAP patients at admission;
platelet count could be considered to be a valuable indicator of
severity and outcome on evaluating hemogram (CBC) values
than the more commonly used leukocyte count.
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